|
Vaccine Comparison
Equid herpesvirus TK mutant vaccine |
NYVAC-EHV-1- vP1014 |
Vaccine Information |
Vaccine Information |
- Product Name: PR1
- Vaccine Ontology ID: VO_0002957
- Type: Live, attenuated vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse, horse
- TK
gene engineering:
- Type: Gene mutation
- Description: This TK mutant is from Equid herpesvirus 1 (Slater et al., 1993).
- Detailed Gene Information: Click Here.
- Immunization Route: intranasal immunization
|
- Vaccine Ontology ID: VO_0004771
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Preparation: vP1014, a vaccinia-based construct (NYVAC) coding for the immediate early gene (gene 64) of EHV-1 (Paillot et al., 2006).
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Host Response |
Mouse Response
|
|
Horse Response
|
Horse Response
- Vaccination Protocol: EHV-primed yearling ponies expressing this haplotype were vaccinated once (n = 1), three (n = 1), or four times (n = 2), and one pony was kept as an unvaccinated control (Paillot et al., 2006).
- Vaccine Immune Response Type: VO_0003057
- Challenge Protocol: The ponies were challenged with EHV-1 (Paillot et al., 2006).
- Efficacy: The results demonstrated that vaccination with a NYVAC-based construct coding for gene 64 stimulated CMI. This immune response alone did not protect against challenge infection. However, the study does illustrate that vaccinia-based vaccines can stimulate CMI in the horse and may therefore contribute to protection against disease caused by EHV-1 (Paillot et al., 2006).
|
References |
References |
Slater et al., 1993: Slater JD, Gibson JS, Field HJ. Pathogenicity of a thymidine kinase-deficient mutant of equine herpesvirus 1 in mice and specific pathogen-free foals. The Journal of general virology. 1993; 74 ( Pt 5); 819-828. [PubMed: 8388018].
|
|
|